# A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)

> **NCT07128251** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Anhui Provincial Hospital** · enrollment: 47 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Immunotherapy
- PD-1
- CTLA-4
- TACE

## Interventions

- **PROCEDURE:** TACE treatment
- **DRUG:** Iparomlimab and Tuvonralimab Injection (QL1706)
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT07128251
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-08-20
- **Primary completion:** 2028-01-30
- **Final completion:** 2029-12-30
- **Target enrollment:** 47 (ESTIMATED)
- **Last updated:** 2025-08-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07128251

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07128251, "A Single-Arm, Multicenter, Exploratory Clinical Study of Transarterial Chemoembolization (TACE) Combined With Iparomlimab and Tuvonralimab Injection and Bevacizumab Injection for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07128251. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*